Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
At Metagenomi, we are creating potentially curative therapeutics using our metagenomics-powered genome editing toolbox.We believe tools with capabilities that go beyond the current technology landscape will be required in order to reach the full therapeutic potential of geno... At Metagenomi, we are creating potentially curative therapeutics using our metagenomics-powered genome editing toolbox.We believe tools with capabilities that go beyond the current technology landscape will be required in order to reach the full therapeutic potential of genome editing. By harnessing the power of metagenomics, the study of genomes recovered from uncultivated organisms in the natural environment, we are discovering and developing a suite of novel genome editing tools with the potential to make any desired therapeutic gene edit, anywhere in the human genome. Show more
Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 31, 2024 NEW...
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, Oct. 28, 2024 NEW YORK, Oct. 28, 2024...
Metagenomi Adenine Base Editors (ABEs) demonstrated over 95% genome targetability Simultaneous ABE triplex editing resulted in over 95% protein knockdown in primary T-cells ABE demonstrated...
Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 17, 2024 NEW...
Poster presentation highlights SMART adenine base editors (ABEs)small enough to be packaged into a single adeno-associated virus (AAV) Data demonstrate compact SMART system optimizations allowing...
Shareholders that lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Oct. 14, 2024 NEW YORK, Oct. 14, 2024 /PRNewswire/...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit - MGX PR Newswire NEW YORK, Oct. 10, 2024 NEW YORK, Oct. 10, 2024 /PRNewswire/...
Shareholders of Metagenomi, Inc. Should Contact The Gross Law Firm Before November 25, 2024 to Discuss Your Rights - MGX PR Newswire NEW YORK, Oct. 7, 2024 NEW YORK, Oct. 7, 2024 /PRNewswire/...
Investors who lost money on Metagenomi, Inc.(MGX) should contact The Gross Law Firm about pending Class Action - MGX PR Newswire NEW YORK, Sept. 30, 2024 NEW YORK, Sept. 30, 2024 /PRNewswire/...
EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.1485 | 7.425 | 2 | 2.17 | 1.92 | 282417 | 2.01096565 | CS |
| 4 | 0.0485 | 2.30952380952 | 2.1 | 2.17 | 1.85 | 266259 | 1.97191973 | CS |
| 12 | -1.2515 | -36.8088235294 | 3.4 | 3.63 | 1.85 | 236041 | 2.28368703 | CS |
| 26 | -4.8715 | -69.3945868946 | 7.02 | 8.1747 | 1.85 | 152654 | 3.13242068 | CS |
| 52 | -8.1015 | -79.0390243902 | 10.25 | 12.74 | 1.85 | 164507 | 5.78619051 | CS |
| 156 | -8.1015 | -79.0390243902 | 10.25 | 12.74 | 1.85 | 164507 | 5.78619051 | CS |
| 260 | -8.1015 | -79.0390243902 | 10.25 | 12.74 | 1.85 | 164507 | 5.78619051 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
